Malaysia's state-owned agri-business conglomerate FELDA is looking to tap growing demand for botanical drugs and treatments with a planned $300 million IPO (Initial Public Offering) of its life sciences unit on the Nasdaq exchange by March 2015, a press release confirmed.
Felda Wellness Corp (IPO-FWCP.O) is a unit of the Federal Land Development Authority of Malaysia (FELDA). The company had for long been thinking about going public and finally announced the listing today. It has chosen to list on the U.S. market for technology and biotech companies because of the country's well developed market for health products and U.S. investors' familiarity with such offerings, they said.
The only other Malaysian firm to have announced a Nasdaq listing is MOL Global Pte Ltd (IPO-MOLL.O), an online payment firm that also owns social networking site Friendster Inc. The company plans to raise $300 million from its U.S. IPO scheduled for this year end. Felda Wellness has been working with a New York-based investment bank with expertise in raising funds for life sciences companies in the United States. Bankers to advice on the deal will be chosen in September after the listing is approved by the FELDA board.
5 Best Regional Bank Stocks To Invest In Right Now: Prima BioMed Ltd (PBMD)
Prima BioMed Ltd is a biotechnology company is engaged in the development and commercialization of medical therapies with a focus on oncology. Its product candidates in development include Cvac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumour types, and an oral formulation for the human papilloma virus (HPV), vaccine. Its product candidate Cvac is a dendritic cell therapy, for which it is conducting a Phase IIb trial for the treatment of ovarian cancer. Cvac is designed to target the tumour antigen mucin-1, which is expressed at high levels on different tumour types. It also has two preclinical product development programs. In May 2011, Prima BioMed GmbH, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in Germany. In May 2011, Prima BioMed Middle East FZLLC, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in the United Arab Emirates. Advisors' Opinion:- [By Monica Gerson]
Prima Biomed (NASDAQ: PBMD) shares dipped 38.59% to touch a new 52-week low of $1.44 after the company reported top-line analysis of CVac Phase 2 trial.
- [By Monica Gerson]
Prima Biomed (NASDAQ: PBMD) dropped 38.17% to $1.45 after the company reported top-line analysis of CVac Phase 2 trial.
Tower Group International (NASDAQ: TWGP) plummeted 24.31% to $10.49. Tower Group announced its plans to release its Q2 results during the week of October 7, 2013. FBR Capital downgraded the stock from Outperform to Market Perform.
- [By Bryan Murphy]
Were it the first time, or even the second time, it happened, it might be dismissible. A third time though? As they say, the third time is the charm. If the old saying applies in the worlds of small cap stocks (and it usually does), then Prima Biomed Ltd. (NASDAQ:PBMD) just kick-started what could be a trade-worthy rally.
Best Life Sciences Companies For 2014: The Bancorp Inc.(TBBK)
The Bancorp, Inc. operates as the holding company for The Bancorp Bank that provides various commercial and retail banking and related products and services to small and mid-size businesses and their principals. The company?s deposit products include checking accounts, savings accounts, health savings accounts, money market accounts, individual retirement accounts, certificates of deposit, and stored value and payroll cards, as well as commercial accounts, such as general commercial checking, small business checking, business savings, and business money market accounts. Its loan portfolio comprises commercial term loans, commercial mortgage loans, commercial lines of credit, 1-4 family construction loans, direct lease financing, and commercial construction, acquisition, and development loans; and consumer loans comprising loans for consumers to finance personal residences, automobiles, home improvements, and for other purposes. The company also provides other banking serv ices, which include private label banking and merchant card processing services; and Internet banking services. It serves Philadelphia, Delaware, Chester, Montgomery, Bucks, and Lehigh counties in Pennsylvania; New Castle county in Delaware; and Mercer, Burlington, Camden, Ocean, and Cape May counties in New Jersey. The company was founded in 1999 and is based in Wilmington, Delaware.
Advisors' Opinion:- [By Ben Levisohn]
The Bancorp (TBBK) plunged 30% to $11.37 this week, earning it the honor of the biggest loser in the Russell 2000. The Bancorp said in a filing that the FDIC had demanded it to more to comply with the Bank Secrecy Act.
Best Life Sciences Companies For 2014: Granite Construction Inc (GVA)
Granite Construction Incorporated (Granite), incorporated on January 24, 1990, is a diversified heavy civil contractors and construction materials producers in the United States. The Company operates in four segments: Construction, Large Project Construction, Construction Materials and Real Estate. The Company operates nationwide, serving both public and private sector clients. Within the public sector, it primarily concentrates on heavy-civil infrastructure projects, including the construction of roads, highways, mass transit facilities, airport infrastructure, bridges, dams and other infrastructure related projects. Within the private sector, it performs site preparation and infrastructure services for residential development, commercial and industrial buildings, and other facilities. The Company owns and leases substantial aggregate reserves and own a number of construction materials processing plants. It also has contractor-owned heavy construction equipment fleets in the United States. In December 2012, it purchased 100% interest of Kenny Construction Company (Kenny).
Construction
Revenue from its Construction segment was approximately 47% of its total revenue during the year ended December 31, 2012. Revenue from its Construction segment is derived from both public and private sector clients. The Construction segment performs various heavy civil construction projects with a large portion of the work focused on new construction and improvement of streets, roads, highways, bridges, site work and other infrastructure projects. These are typically bid-build projects completed within two years.
Large Project Construction
Revenue from its Large Project Construction segment was 41.4% of its total revenue in 2012. The Large Project Construction segment focuses on large, complex infrastructure projects, which typically have a longer duration than its Construction segment work. These projects include major highways, mass transit facilities, bridges, tunn! els, waterway locks and dams, pipelines, canals and airport infrastructure. This segment primarily includes bid-build, design-build and construction management/general contractor contracts. It participates in joint ventures with other construction companies mainly on projects in its Large Project Construction segment. Joint ventures are typically used for large, technically complex projects, including design/build projects, where it is desirable to share risk and resources. Joint venture partners typically provide independently prepared estimates, shared financing and equipment and often bring local knowledge and expertise.
The Company also utilizes the design/build and construction management/general contract methods of project delivery. Under the construction management/general contract method of delivery, it contracts with owners to manage the design phase of the contract with the understanding that it will negotiate a contract on the construction phase when the design nears completion. Revenue from design/build and construction management/general contract projects represented 74.5% of Large Project Construction revenue in 2012.
Construction Materials
Revenue from its Construction Materials segment was 11.1% of its total revenue in 2012. The Construction Materials segment mines and processes aggregates and operates plants that produce construction materials for internal use and for sale to third parties. It has aggregate reserves that it has acquired by ownership in fee or through long-term leases. Aggregate products used in its construction projects represented approximately 42.7% of its tons sold during 2012.
Real Estate
Granite Land Company (GLC) is an investor in a diversified portfolio of land assets and provides real estate services for other Granite operations. GLC�� investment portfolio consists of residential, as well as retail and office site development projects for sale to home and commercial property developers. The range! of its i! nvolvement in an individual project may vary from passive investment to management of land use rights, development, construction, leasing and eventual sale of the project. Generally, GLC has teamed with partners who have local knowledge and expertise in the development of each property. GLC�� investments are located in Washington, California and Texas. Revenue from GLC was 0.2% of its total revenue in 2012.
Advisors' Opinion:- [By Wallace Witkowski]
Some of the companies most dependent on government for revenue are Harris Corp. (HRS) �with 80% of revenue government-derived; Granite Construction Inc. (GVA) �with 58%; Flir Systems Inc. (FLIR) �with 54%; and Waste Management Inc. (WM) � and Republic Services Inc. (RSG) �both with 50%, according to Goldman Sachs.
Best Life Sciences Companies For 2014: Compagnie Generale des Etablissements Michelin SCA (ML)
Compagnie Generale des Etablissements Michelin SCA (Michelin SCA) is a France-based company, which is mainly engaged in the manufacture and distribution of tires for a variety of vehicles. In addition, it publishes maps and guides, and offers digital products and services. The Company�� main activity is the production of tires for passenger cars, two-wheeled vehicles, trucks, agricultural equipment and aircraft, among others, which are sold through such distribution divisions as Euromaster in Europe and TCI in the United States. Michelin SCA also offers travel assistance services, including maps and guides, and digital navigation products and services, via ViaMichelin. In addition, the Company produces a number of lifestyle products, such as car and bike accessories, work, sport and leisure gear, and collectibles. The Company is active domestically and abroad. Advisors' Opinion:- [By Corinne Gretler]
Michelin & Cie. (ML) increased 2 percent to 70.55 euros after UBS raised Europe�� largest tiremaker to buy from neutral, citing improved cost positions that enable more competitive pricing and higher profits.
Best Life Sciences Companies For 2014: First Trust Exchange Traded Fund (FVL)
First Trust Value Line 100 Fund (the Fund) is a diversified closed-end management investment company. The Fund seeks to outperform the Standard & Poor's 500 Composite Stock Price Index (the S&P 500 Index) by adhering to a strategy of investing in a diversified portfolio of the 100 common stocks ranked number 1 in Value Line's Timeliness Ranking System. The Fund invests 80% of its net assets in the stocks that are ranked number one in the Value Line Timeliness Ranking System. As of March 31, 2006, the Fund had invested in sectors, such as household durables, metals and mining, specialty retail, oil and gas, software, machinery, hotels, restaurants and leisure, computers and peripherals, biotechnology, information technology services, and textiles, apparel and luxury goods.
As of March 31, 2006, the Fund's top 10 holdings were Palm, Inc., United INDL Corp., AAR Corp., Accenture LTD, Citrix Systems, Inc., Cymer Inc., Guess, Inc., Henry Jack & Assoc., Inc., Micrel Inc. and Molecular Devices Corp. The Fund had a large capitalization orientation to its portfolio holdings as of December 31, 2005. As of December 31, 2005, the 100 stocks in the portfolio consisted of large-cap stocks (34), mid-cap stocks (35) and small-cap stocks (31). During the year ended December 31, 2005, the Fund posted a net asset value (NAV) total return of 11.9% and a market value total return of 7.5%. This compared to a gain of 4.8% for the S&P 500 Index. The Fund's investment advisor is First Trust Advisors, L.P.
Advisors' Opinion:- [By David Trainer]
First Trust Value Line 100 ETF (FVL) is in the Danger Zone this week. FVL is another example of a supposedly "passive" ETF that purportedly tracks an index but actually resembles an actively managed portfolio. FVL's methodology tracks an index, but it is an index in name only.
- [By David Trainer]
First Trust Value Line 100 ETF (FVL) is my worst-rated All Cap Blend ETF and Clarity Fund (CLRTX) is my worst-rated All Cap Blend mutual fund. FVL earns my Dangerous rating, while CLRTX gets my Very Dangerous rating.
Best Life Sciences Companies For 2014: Tranzyme Inc.(TZYM)
Tranzyme, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of acute and chronic gastrointestinal (GI) motility disorders in the United States and internationally. The company?s clinical product candidates include ulimorelin, an intraveneous ghrelin agonist, which is in the Phase III clinical development stage for the treatment of acute upper GI motility disorders; and TZP-102, an orally-administered ghrelin agonist that has commenced Phase IIb clinical development stage for the treatment of diabetic gastroparesis. Its preclinical product candidates comprise TZP-201, a motilin antagonist for the treatment of various forms of moderate-to-severe diarrhea; and TZP-301, an oral ghrelin antagonist for the treatment of metabolic diseases. The company has strategic collaboration with Bristol-Myers Squibb Company to discover, develop, and commercialize additional novel co mpounds; and a license agreement with Norgine B.V to develop and commercialize ulimorelin in Europe, Australia, New Zealand, the Middle East, and north and South Africa. Tranzyme, Inc. was founded in 1998 and is headquartered in Durham, North Carolina.
Advisors' Opinion:- [By CRWE]
Tranzyme Pharma (Nasdaq:TZYM) reported that it has closed the previously announced underwritten registered direct offering of approximately 3.0 million shares of its common stock at a price of $3.85 per share for gross proceeds, including the over-allotment option, of approximately $11.5 million.
No comments:
Post a Comment